PTN — Palatin Technologies, Inc.
$5.11-7.26%
Last close: · regular session
After-hours $5.01 -1.96% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for PTN in the TickerWise workspace.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: AMEX
- Employees: 30
- Website: https://palatin.com
Latest SEC filings for PTN
Latest PTN news
- Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript Read article
- Palatin Technologies GAAP EPS of -$1.11, revenue of $0.3M Read article
- Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.